Search

everythinglearnresearchcommunity

for

Search:↓

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Ruxolitinib cream may help treat severe hair loss in children.

Norgalanthamine helps hair cells grow by activating certain pathways related to hair growth.

New treatments for cancer and skin disorders show promise in disrupting harmful cell interactions and promoting hair growth.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

All-trans-retinoic acid stops mink hair growth by affecting cell growth and causing cell death.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Integrin-linked kinase is crucial for normal skin healing.

Inhibiting certain proteins harms hair follicle immunity and increases IL-33, affecting hair health.

Patients with alopecia areata prefer treatments that regrow scalp hair quickly over how often they need to take the medication.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

Certain gene variations in EGF and EGFR may increase the risk of alopecia areata in Koreans.

Ebastine may promote hair regrowth by increasing cell growth through the ERK pathway.

JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.

Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.